Experimental Treatment of Placental Insufficiency in Animal Model (by IGF-1)

Murashko A.V.¹, Ishenko A.I.², Magomedova Sh.M.³, Didikin S.S.⁴, Zinovyeva L.V.⁵, Pavlova L.A.⁶, Kozin S.V.⁷ and Drapkina J.S.^8,

¹Department of obstetrics/gynecology №1, University Hospital №2, Sechenov First Moscow State Medical University, Russia

²Snegirev Hospital of Obstetrics/gynecology, Sechenov First Moscow State Medical University, Russia

³Department of obstetrics/gynecology №1, Sechenov First Moscow State Medical University, Russia

⁴Surgical Anatomy department, Sechenov First Moscow State Medical University, Russia

⁵Central vivarium, Sechenov First Moscow State Medical University, Russia

⁶Laboratory of Biologically Active Compounds, pharmacological sciences, Sechenov First Moscow State Medical University, Russia

⁷Department of pharmacology, biological sciences, Sechenov First Moscow State Medical University, Russia

⁸Obstetrics/Gynecology, First Moscow Medical University, Russia

Cite this paper:
Murashko A.V., Ishenko A.I., Magomedova Sh.M., Didikin S.S., Zinovyeva L.V., Pavlova L.A., Kozin S.V. and Drapkina J.S.. Experimental Treatment of Placental Insufficiency in Animal Model (by IGF-1). American Journal of Clinical Medicine Research. 2016; 4(2):34-37. doi: 10.12691/ajcmr-4-2-4

Abstract

Introduction: Fetal growth restriction occurs in up to 10 % of pregnancies, and is one of the major causes of infant mortality. The primary cause of fetal growth restriction is placental insufficiency. We suggest that insulin-like growth factor-1(IGF-1) is effective in improving placental blood circulation and corrects fetal weight deficits in animal models. Materials and Methods: The experiment was conducted in 18 pregnant Wistar rats. The animals were divided into 3 groups (intact group- laboratory rats without PI receiving placebo ; control group- laboratory rats with PI receiving placebo; experimental group- laboratory rats with PI model receiving IGF-1 via subcutaneous injections. This study was carried out in strict accordance with the recommendations in the Guide of European convention for the Protection of Vertebral Animals. The protocol was approved by the Intercollegiate Committee on the Ethics of Animal Experiments (Association of Medical universities and universities for Pharmacy & Pharmacology: Permit Number: 11-10). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. Results: All rats without PI had spontaneous labor by the end of the pregnancy. In intact group, average number of newborn rats were 9,5±1,96 and the average weight of one newborn rats was 7,38±0,095 grams. In the control group all rats delivered hypotrophic fetuses. Number of newborns in broods and their body weight did not differ significantly in the experimental animal group comparing with intact group. The mean number of newborn rats in the control group was 10,0±1,05 with the mean body mass 7,44±0,138г. Offspring's number was 25 % higher in animals treated with IGF-1 compared with the intact group (p ≤ 0,05). Discussion: Our method gave valid and reliable information proving subcutaneus insulin growth factor-1 administration reduced fetal growth restriction associated with placental insufficiency. Insulin growth factor-1 acts in response to such signals as nutrients, oxygen and hormones via the IGF receptors, and the insulin receptor. Deletion of IGF-1 gene leads to reduced birth weight.

Keywords:
placental insufficiency insulin growth factor-1 fetal growth restriction placental blood circulation animal models placentome uterine artery coagulation

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Murashko L.E. and co-authors, Perinatal outcomes in chronic placental insufficiency, Obstetrics/Gynecology, 1996; 4: 43-45.
[2]	Sidorova I.S., Makarov I.O, Fetalplacental insufficiency: clinical and diagnostic aspects -2000. [1], Znanie-M, Moscow, p.125-127.
[3]	Bloomfield FH, Bauer MK, van Zijl PL, Gluckman PD, Harding JE 2002 Amniotic IGF-I supple ments improve gut growth but reduce circulating IGF-I in growth-restricted fetal sheep.// Am J Physiol. Vol.- 282, - P.269 -289.
[4]	Brubaker PL The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. // 2006 Ann NY AcadSci Vol. 70, P.10-26.
[5]	Bloomfield FH, van Zijl PL, Bauer MK, Harding JE 2002 A chronic low dose infusion of insulin-like growth factor-I alters placental function but does not affect fetal growth.// Reprod. Fertil. Vol. 14, P. 393-400.
[6]	De Boo HA, Harding JE The developmental origins of adult disease (Barker) hypothesis. // J ObstetGynaecol 2006, Vol. 46, P. 4-14.
[7]	De Boo HA, Van Zijl PL, Smith DEC, Kulik W, Lafeber HN, Harding JE Arginine and mixed amino acids increase protein accretion in the growth restricted and normal ovine fetus by different mechanisms. // Pediatr Res 2005, Vol.58, P. 270-277.
[8]	Kim WK, Ryu YH, Seo DS, Lee CY, Ko Y 2006 Effects of oral administration of insulin-like growth factor-I on circulating concentration of insulin-like growth factor-I and growth of internal organs in weanling mice. // Med. Sci. Vol. 63, P167-170.
[9]	Rasmussen S, Irgens LM. History of fetal growth restriction is stronger associated with severe rather than milder pregnancy-induced hypertension. // Hypertension 2008, Vol. 51, P.1231-1238.
[10]	Shaikh S, Bloomfield FH, Bauer MK, Phua HH, Gilmour RS Amniotic IGF-I supplementation of growth-restricted fetal sheep alters IGF-I and IGF receptor type 1 mRNA and protein levels in placental and fetal tissues.// J. Endocr., Vol. 186, P. 145-155.
[11]	Sholook MM, Gilbert JS, Sedeek MH, Huang M, Hester RL Systemic homodynamic and regional blood flow changes in response to chronic reductions in uterine perfusion pressure in pregnant rats. // J Physiol Heart CircPhysiol 2007; Vol.293, P.2080-2084.
[12]	Simona C. Eremia, Hendrina A. de Boo, Frank H. Bloomfield, Mark H. Fetal and Amniotic Insulin-Like Growth Factor-I Supplements Improve Growth Rate in Intrauterine Growth Restriction Fetal Sheep. // J Endocrinology 2007 Vol. 148, P.2963-2972.
[13]	Wiliams M.A., Mahomed K., Farrand A. et al. Plasma Tumor Necrosis Factor-a Solube Receptor p55 (sTNF p55) Concentration in Eclamptic, PreeclampticandNormotensivePregnant Women. 11th World Congressofthe International Society forthe Study of Hypertension in Pregnancy (ISSHP). 572.// J ReprodImmunol. 1998 Nov; 40(2):159-73.
[14]	Crombleholme T, Habli M, Jones H: Regulation ofaminoacidtransportersbyadenoviral-mediated human insulin-like growth factor-1 in a mousemodelofplacentalinsufficiency in vivo andthe human trophoblastlineBeWo in vitro. // Placenta. 2014 Feb; 35(2):132-8.
[15]	Fowden, A.L.; Forhead, A.J.; Coan, P.M.; Burton, G. The placentaand intrauterine programming. J. Neuroendocrinol. 2008, 20, 439-450.
[16]	Sferruzzi-Perri, A.N.; Owens, J.A.; Pringle, K.G.; Roberts, C.T. The neglected role of insulin-like growth factors in the maternal circulation regulating fetal growth. J. Physiol. 2011, 589, 7-20.
[17]	Ward, J.W.; Forhead, A.J.; Wooding, F.P.B.; Fowden, A.L. Functional significance and cortisol dependence of the gross morphology of ovine placentomes during late gestation. Biol. Reprod. 2006, 74, 137-14518.
[18]	Kazantzis, M.; Stahl, A. Fatty acid transport proteins, implications in physiology and disease. Biochim. Biophys. Acta 2012, 1821, 852-857.
[19]	Vonnahme, K.A.; Arndt, W.J.; Johnson, M.L.; Borowicz, P.P.; Reynolds, L.P. Effect of morphology on placentome size, vascularity and vasoreactivity in late pregnant sheep. Biol. Reprod. 2008, 79, 976-982.
[20]	Barker, D.J.P.; Thornburg, K.L. Placental programming of chronic diseases, cancer and lifespan: A review. Placenta 2013, 34, 841-845.